Additionally, we identified a significant interaction of PIK3CA mutation status and aspirin use, whereby PIK3CA mutations were associated with longer time to metastasis and survival among aspirin non-users, but non-significant faster progression to metastatic disease and increased mortality risk among aspirin users. Here, PIK3CA is linked to metastatic neoplasm.